Ranbaxy Declines After Recall of Generic Lipitor in U.S.

Ranbaxy Laboratories Ltd. fell the most in more than three months after announcing a recall of the company’s generic version of Pfizer Inc.’s cholesterol treatment Lipitor.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.